In the RELATIVITY-047 Phase II/III trial combining Bristol Myers Squibb’s Opdivo with the anti-LAG-3 antibody relatlimab, the drug mashup met the study’s primary goal for progression-free survival compared to use of the blockbuster brand alone in metastatic melanoma patients.
Pfizer Inc. started an early-stage U.S. trial of an oral Covid-19 antiviral therapy that could be prescribed to patients at the first sign of infection, the company said on March 23.
Pfizer Inc. and BioNTech SE said on March 10 that real-world data from Israel suggests their Covid-19 vaccine is 94 percent effective in preventing asymptomatic infections, meaning it could significantly reduce transmission.
BioNTech SE could have capacity to make 3 billion doses of the Covid-19 vaccine the company developed with partner Pfizer Inc. during 2022, Bloomberg News reported on March 9, citing an interview with the German company’s chief executive officer.
The United States identified three online publications directed by Russia’s intelligence services that it says are seeking to undermine Covid-19 vaccines produced by Pfizer and Moderna, a State Department spokeswoman said.
The United States must stick to a two-dose strategy for the Pfizer-BioNTech and Moderna Covid-19 vaccines, top U.S. infectious disease official Anthony Fauci told the Washington Post newspaper.
The U.S. Food and Drug Administration on Feb. 25 approved storage and transportation of COVID-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE at standard freezer temperatures for up to two weeks instead of ultra-cold conditions.
The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing Covid-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies.
Covid-19 vaccine makers told Congress on Feb. 23 that U.S. supplies should surge in the coming weeks due to manufacturing expansions and new vaccine authorizations.
The U.S. Food and Drug Administration accepted for Priority Review Pfizer Inc.’s Biologics License Application for TicoVac, the company’s tick-borne encephalitis vaccine for active immunization to prevent TBE in individuals 1 year of age and older.
